| abstract |
The present invention relates to methods and compositions for directing T cells to CD70 for immunotherapy of CD70 positive malignancies. In aspects of the invention, CD70 specific T cells are employed. In a particular aspect, it relates to T cells that express novel molecules comprising the full length CD70 receptor (CD27) fused to the zeta signaling domain of the T cell receptor complex. Such T cells recognized CD70 positive tumor cells and had cytolytic activity against CD70 positive tumor cells. [Selection] Figure 1AB |